- Cognitive impairment - which prevents the normal accomplishment of tasks of daily living such as cooking, cleaning etc.
- A deline in memory- makes independant living impossible
- A deline in thinking, planning and organising daily activities
- Gradual loss of orietation in space and time
- A deline in emotional control or motivation or a change in social behaviour
- Alzheimer's disease (AD)
- parkinson's disease (PD)
Aetiology
- AD is characterised by both cell structure and biochemical changes
- Amyloid plaques are formed by the accumulation of beta-amyloid of tau proteins. The reasons why these occur are not understood.
1st explaination
- Amyloid precursor protein (APP) abundantly expressed in the membranes of many nerve & gila cells and they are used as function for cell structure and cell-cell recognition.
- In normal life APP is produced and then secretase enzymes sever the chain and release A-beta peptide into the extrecellular space.
* In AD, too much A-beta is produced or it is not being removed properly - so formed the beta-amyloid plaques.
- as the plagues increase in size, they appear to stimulate an autoimmune inflammatory response.
- they inferfere with synaptic function and the regulation of transmitter reuptake.
- excess extracellular transmitter due to impaired reuptake may generate excitoxicity; so eventually cells adjacent to the plaques die.
2nd explaination
- it is also thought that declining memory and cognitive function results from a lack of acetylcholine and an excess of excitatory amine acids, especially glutamate
- Acetlycholine is normally broken down by 2 cholinesterase enzymes, actylcholinesterase and butyrylcholinesterase. In AD, the deline in activity of acetylcholine in accompanied by a decrease in the production of acetylcholinesterase, further contributing to the deline of acetylcholine levels.
- Glutamate is a major excitatory neurotransmitter. Its action on the NMDA ( N-methyl-D-aspartate) receptor can lead to overstimulation of neurones, causing permanant damage.
Hypothese on causes of AD
- Genetic factors : Faulty genes
- Environmental Factors : Health and degeneration
- Female ( Because females tend to live longer than males)
- Head injury
- Parkinson's disease
- hypothyroidism
- chronic exposure to aluminium
- cardiovascular disease
- smoking
- chronic high alcohol intake
Sign and symptoms
AD is characterised by a gradual decline in cognitive and memory function. Therefore, it can present in many ways. Physical signs are:
- unable to perform daily activities, such as dressing, washing, feeding
- behaviour problems
- reduced muscular function
- sleeplessness
- aggression
- apathy - the feeling of not being interested in or enthusiastic about anything
- delusion and hallucinations
- loss of autonomic control
- Amnesia - memory impairment ( impaired ability to learn new information or recall info)
- Aphasia - Language disturbance
- Apraxia - impaired ability to carry out motor activities despite intact motor function
- Agnosia - failure to recognise or identify objects despite intact sensory function
- Disturbance in executive function ( planning, organising, sequencing and abstracting)
Faulty Genes
- Chromosome 21: APP gene
- Chromosome 19: APO E4, a form of apolipoprotein
- Chromonsome 1 & 14: Protein called prosenilin-2 & presenillin-1
- it is a plasma lipoprotein that is one of the principal constituents of chylomicrons and a very low density lipoprotein (VLDL)
- it plays a vital role in cholesterol transport in the blood.
- 3 known isoforms of APO E, coded by APO E2, APO E3 and APO E4 genes.
- APO E4 genotype : implicated as a risk factor for AD
- Recent studies : APO E4 may influence the CNS 's response to injury
- As the condition predominately affects cognitive and memory functions, the investigations focus on these areas rather than physical examinations.
- it is also possibke to make a presumed diagnosis of AD, as a definiti diagnosis in only possible through autopsy
- A number of assessment methods can be utilised that define both cognitive and memory function. This includes:
- Mini Mental State Examination (MMSE) - 5 x cognitive Domain Tested
- Orientation: ( what day of the week is it? / what building are we in? )
- Memory (1) : Immediate word recall
- Attention & calculation: Counting & spelling backwards
- Memory (2) : Delayed recall
- Language Writing & drawing: Shown 2 daily item & name them. Following simple instructions, sentence writing & intersecting shape drawing.
- Orientation: ( what day of the week is it? / what building are we in? )
- Alzheimer's disease Assessment Scale
- The blessed test of information
- MRI ( Magnetic Resonance Imagining) - AD's patients shown enlarged ventricles and sulci
- CT
- PET (Position emission Tomography) scans- show the differences in brain activity between a norma brain and a brain affected by AD.
- Four drugs are currently available in the UK
- Cholinesterase inhibitors- donepezil
- Galantamine
- Rivastigmine
- NMDA-receptor antagonist - Memantine
- Approximately 30-50% of patients show a definable decrease in their rate of cognitive decline after 3 months of treatment.
- the same degree of modest improvement in approx. 30-40% of patients with mild to moderate AD.
- The major effect of CI lies in their potential to reduce severity of symptoms & slow the rate of symptom progression , but it does not cure it.
- they do not stop the essential pathological process.
Mode of action:
- they reversibly bind with and inactivate the enzyme cholinesterase which breaks down acetylcholine.
- they potentiate the duration of action of ACh in the cholinergic synapse.
- The main adverse effects are from their cholinergic activity, such as nausea, vomiting, diarrhoea, anorexia, urinary frequency and depression.
- This can be a problemas those with AD often losing weight through the disease
Dose
- One 5mg tablet daily ( can be increase up to 10mg over 4 weeks)
Mode of action
- it is a reversible non competitive inhibitor of acetylcholinesterase + direct nicotinic agonist. They bind to inactivate the enzymes to breakdown acetylcholine and act as an agonist to acetylochine nicotinic receptors.
- N/V
- Dizziness
- agitation ( an state of excitment, disturbance or worry)
- one 4 mg tablet twice daily for 4 weeks. ( can be increased up to 8mg twice daily for 4 weeks then maintain 8-12 mg twice daily)
Mode of action:
- same as Donepezil
- N/V
- confustion
- angina
- agitation
- one 1.5mg table twice daily, increased by 1.5mg gradually.
Memantine
Mode of action
- Glutamate transmits its signal via the NMDA receptor.
- NMDA receptor activation and Ga2+ influx are important for learning processes
- Glutamate is recycled in glial cells
- Beta Amyloid inhibits glutamate recycling
- excessive glutamate masks the neuronal singal transmission.
- so... Memantine blocks effects of excess glutamate and restoration of physiological transmission occurs.
- in result to improvement of the symptoms of AD.
- Dizziness
- confusion
- anxiety
- cystitis
Dose
- One 5mg tablet daily ( can be increased up to 10mg twice daily gradually)